It has been validatedthat agonists targeting FFAR1 can achieve the initial therapeuticendpoints of T2D, and the epimer agonists (R,S) AM-8596 can activate FFAR1 differently, with one actingas a partial agonist and the other as a full agonist. This evidence concerns the gene FFAR1 and type 2 diabetes mellitus.